TheVax Genetics Vaccine and Biotechpharma have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
"The THEVAX HBV vaccine has been developed employing our company patented technology platform, which has enabled us to proceed from process development into cGMP production in a much shorter period of time,” said KinKai (Ben) Hwang, CSO of TheVax Genetics Vaccine. “We are pleased to partner with Biotechpharma as our CDMO for cGMP manufacturing of our molecule entering clinical trials. Biotechpharma' s excellent track record, expertise and capabilities to timely deliver a high quality product will play a significant role in the success of this program."
"We are delighted to be working with TheVax Genetics Vaccine CO on this exciting project and with great enthusiasm look forward to seeing it enter clinical trials," comments Vladas Bumelis, CEO of Biotechpharma. "Biotechpharma is well positioned to facilitate successful process transfer and manufacture of HBV vaccine in rapid time-frames, with focus on high quality and excellence in service."